News Headlines

  1. Mereo BioPharma And Sentynl Therapeutics Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) 8/11/2026

    Mereo BioPharma Group plc (Nasdaq: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (“Zydus”), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.

  2. Sobi Enters Strategic Partnership With Innate Pharma To License Lacutamab In T-Cell Lymphoma 8/10/2026

    Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.

  3. Almirall Enters Collaboration With CrystalO For The Discovery And Development Of Novel Small Molecules In Medical Dermatology 8/10/2026

    Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, today announced a collaboration and licensing agreement with Shenzhen CrystalO Biopharma Technology Co., Ltd. ("CrystalO") to jointly initiate an R&D collaboration for drug discovery in medical dermatology.

  4. Xcellon Biologics Acquires GMP Manufacturing Facility From NextCure, Becoming An End-To-End CRDMO For Next-Generation Bioconjugates And Complex Biologics 8/10/2026

    Xcellon Biologics, a U.S.-based Contract Research, Development and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics, today announced that it has signed a definitive agreement to acquire the GMP biologics manufacturing facility from NextCure, Inc.

  5. Jazz Pharmaceuticals To Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio 8/10/2026

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration.

  6. Amneal Completes Acquisition Of Kashiv BioSciences, Creating A Global Biosimilar Leader 8/10/2026

    Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.

  7. BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration 8/10/2026

    BeOne Medicines Ltd., a global oncology company, and Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.

  8. Innovent Biologics And Daiichi Sankyo Enter Exclusive Agreement For VANFLYTA® Commercialization In China 8/9/2026

    Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in China.

  9. Kyungdong Pharmaceutical And Asimov Announce Completion Of Cell Line Development Campaign For Biosimilar Antibody 8/9/2026

    Kyungdong Pharmaceutical announced that it has successfully completed a cell line development campaign for a biosimilar antibody candidate, in collaboration with Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development.

  10. AuctuCel Launches AuctuPrime, Advancing Safer And More Scalable Cell Therapy Manufacturing 8/8/2026

    Behind every breakthrough cell therapy is a manufacturing process few patients ever see—but one that ultimately determines whether these treatments can reach the people who need them.